KOLINPHARMA®: first patent obtained for Xinprox®
KOLINPHARMA® S.p.A. is pleased to announce that it has obtained the first patent for XINPROX®.
XINPROX®, studied and developed for prostate well-being, is a food supplement whose formulation is based on very high-quality, technologically advanced raw materials supported by scientific studies, such as pollen extract, quercetin, alpha-lipoic acid and L-tryptophan.
Kolinpharma®'s total number of patents thus rises to 46: 7 in Italy, 6 in the USA, 1 in Israel and 32 in the main European countries.
Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to announce that we have obtained the first patent for XINPROX®, which once again shows the soundness of our formulations and of the work done by our Research and Development department and by the whole company. [...] Research is one of our strengths, and for this reason we intend to keep investing in and enhancing our products to offer our customers and patients scientifically validated solutions. A patent stands for synergy, uniqueness and innovation”.

















